Clover Health Investments, Corp
Here’s whether Clover Health Investments, Corp (CLOV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.38% over 10 days); RSI 46 — healthy momentum range; strong 1-year return of +59.0%; 3-month momentum positive (+16.9%). Concerns: below the 50-day MA (medium-term momentum negative). Currently 25.8% off its 52-week high. Score: +5/7.
CLOV is holding above its long-term 200-day MA ($3.06) but has slipped below the 50-day MA ($4.66), pointing to short-term weakness in an otherwise intact trend. An RSI of 45.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +59.0% compares to +20.5% for SPY (beat the market by 38.5%). The current 25.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.